[Novel molecular-targeted drug for renal cancer(AXIS trial)].
Recently, a new tyrosine kinase inhibitor, axitinib, was approved for the treatment of advanced renal cell carcinoma for when one prior systemic therapy fails. The approval was based on an international, randomized, open-label trial(AXIS trial) of patients with metastatic renal cell carcinoma who failed in one prior systemic regimen. The present manuscript summarizes this new drug and the AXIS trial.